



## Zymeworks to Host First Quarter 2022 Results Conference Call

April 19, 2022

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Apr. 19, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May 4<sup>th</sup>, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 4<sup>th</sup>, 2022 at 4:30 p.m. ET.

### Conference Call and Webcast Information:

- Telephone: 844-435-7258 (U.S. or Canada) or +1-631-485-4286 (international)
- The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2 -targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit [www.zymeworksclinicaltrials.com](http://www.zymeworksclinicaltrials.com). For additional information about Zymeworks, visit [www.zymeworks.com](http://www.zymeworks.com) and follow [@ZymeworksInc](https://twitter.com/ZymeworksInc) on Twitter.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220419005147/en/): <https://www.businesswire.com/news/home/20220419005147/en/>

Jack Spinks  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

Media Inquiries:  
Diana Papove  
(604) 678-1388  
[media@zymeworks.com](mailto:media@zymeworks.com)

Source: Zymeworks Inc.